The development of novel treatments that selectively inhibit the RAS-RAF-MAPK pathway
represents a milestone in the history of melanoma treatment. BRAF mutations occur in …

Abstract The RAS/RAF/MEK/ERK pathway has been reported to be activated in over 80% of
all cutaneous melanomas, making it the focus of many scientific studies in the melanoma …

New drugs targeting the mitogen-activated protein kinase (MAPK) pathway have generated
striking clinical response in melanoma therapy. From the discovery of BRAF mutation in …

A phase II trial comparing dual MAPK pathway inhibition by combining BRAF and MEK
inhibitors with BRAF inhibition alone showed increased progression-free survival and …

The mitogen-activated protein kinase (MAPK) pathway is critical to oncogenic signaling in
the majority of patients with malignant melanoma. Driver mutations in both NRAS and BRAF …

Melanoma is the most lethal form of skin cancer. Melanoma is usually curable with surgery if
detected early, however, treatment options for patients with metastatic melanoma are limited …

The treatment of melanoma has been revolutionized over the past decade with the
development of effective molecular and immune targeted therapies. The great majority of …

Opinion statement Melanoma is the most aggressive of the cutaneous malignancies,
causing more than 9,000 deaths in the past year in the United States. Historically, systemic …

Introduction: Melanoma is an aggressive disease characterized by a complex etiology. The
discovery of key driving mutations (primarily BRAF mutations) led to the development of …

The mitogen-activated protein kinase (MAPK) cascade is an intracellular signaling pathway
involved in the regulation of cellular proliferation and the survival of tumor cells. Several …